Our Story

VascuBio Innovation was founded by McGill University and Harvard-trained researchers to build more effective tools for drug screening and biomedical innovation. We develop advanced platforms at the intersection of microfluidics, biomaterials, and biofabrication to help researchers and industry study human biology more accurately, reduce reliance on animal models, and accelerate the development of better therapies. This focus on bioreactors and screening platforms is consistent with VascuBio’s stated mission to advance tissue engineering and drug development tools.

Where It All Began

VascuBio began with years of academic research in biomaterials, microfluidics, tissue engineering, and organ-on-chip technologies. During this work, we saw a clear gap between strong research and practical tools that could be adopted for real drug development workflows.

Part of our foundation builds on research and intellectual property developed through academic environments, including work connected to McGill University. The company was created to translate that scientific foundation into scalable technologies with real-world impact, especially in drug screening and advanced in vitro models.

Mission & Vision

Mission

Accelerating Regenerative Medicine

To accelerate drug discovery and regenerative medicine by building advanced screening and tissue-engineering platforms that are precise, scalable, and accessible.

Vision

Accessible Healthcare for All

A future where better human-relevant models enable faster drug development, reduce reliance on animal testing, and improve patient outcomes worldwide.

Our Team

Built by scientists and engineers translating research into real-world biotechnology

VascuBio is led by researchers and entrepreneurs with deep experience in biomedical engineering, microfluidics, biomaterials, and translational biotechnology. Our team works closely with leading academic institutions and industry partners to bring advanced biomedical technologies from the lab to real-world applications.

Pooya Saberi, MEng

Co-Founder & CEO

Biotechnology entrepreneur with experience building and scaling biomedical ventures, focused on translating advanced research into commercial technologies for drug screening, diagnostics, and tissue engineering.

Vahid Karamzadeh, PhD

Co-Founder & CTO

Biomedical engineer with research experience at Harvard Medical School and McGill University, focused on microfluidics, biomaterials, and biofabrication for drug screening and tissue engineering, with 15+ peer-reviewed publications.

Navid Tavoosi, MEng

Research Scientist II

Mechanical engineer and McGill MSc alumnus with expertise in biomaterials and 3D printing, leading bioreactor design at VascuBio.

Margaret Bywater, MD

Advisor & mentor

Pathologist, and biotechnology executive, serving as District 3 Bio Stream Lead and co-founder of Morphocell Technologies, which completed a US$50M Series A to advance its regenerative medicine platform.

Luc Mongeau, PhD

Scientific Advisor

Chair of Mechanical Engineering and Distinguished James McGill Professor at McGill University, with expertise in biomechanics, aeroacoustics, and tissue engineering, particularly voice production and vocal fold regeneration.

Core Values

Scientific Rigor

Our technologies are built on strong scientific foundations, rigorous experimentation, and peer-reviewed research.

Translational Innovation

OWe focus on transforming breakthrough research into practical platforms for drug discovery and biomedical applications.

Collaboration

We work closely with academic researchers, clinicians, and industry partners to accelerate innovation.

Impact on Human Health

Every technology we develop aims to improve how diseases are studied, diagnosed, and treated.